Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise
Editas Medicine, Inc. (EDIT), announced that it has entered into a definitive agreement with the private Shoreline Biosciences (Shoreline) to license Editas Medicine’s proprietary SLEEK (SeLection by Essential-gene Exon Knock-in) and AsCas12a gene editing technologies and acquire Editas Medicine’s preclinical . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.